ConductScience.org, home

Paper2890636

The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions.

Boucek RJ and 5 others. J Biol Chem, 1987. Cited by 137 papers, by iCite.

Cite this record

ConductScience Library. The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions. Papers, record 2890636. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2890636

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions.
PubMed
Journal
J Biol Chem
PubMed
Year
1987
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
137
iCite
Relative citation ratio, by iCite
4.51
iCite
Revised in PubMed
2021-02-10
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Boucek RJ JrR J
2Olson RDR D
3Brenner DED E
4Ogunbunmi EME M
5Inui MM
6Fleischer SS

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Adenosine TriphosphatasesMajor topic
DoxorubicinMajor topic
MyocardiumMajor topic
Sarcoplasmic ReticulumMajor topic
5'-Nucleotidase
Animals
Ca(2+) Mg(2+)-ATPase
Calcium-Transporting ATPases
Dogs
Heart
Kinetics
Nucleotidases
Proton-Translocating ATPases
Sodium-Potassium-Exchanging ATPase

Source PubMed

Download CSV of topics

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
HL 28711NHLBI NIH HHSUnited StatesR23HL028711PubMed and NIHNIH RePORTER
HL 32711NHLBI NIH HHSUnited StatesR01HL032711PubMed and NIHNIH RePORTER
HL 33060NHLBI NIH HHSUnited StatesR01HL033060PubMed and NIHNIH RePORTER

Download CSV of grants

Cited by46

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 137 citations.

PMIDTitleJournalYearIn PapersSource
41252081TLD-1, a Novel Liposomal Doxorubicin, in Patients with Solid Tumors: Comparative Pharmacokinetics and Final Results of a Multicenter Phase 1 Study (SAKK 65/16).Clin Pharmacokinet2026https://conductscience.org/library/papers/41252081PubMed
40481868Daunorubicin and its hydroxy metabolite in cardiomyocytes: insights into cellular kinetics, toxicity, DNA damage, and dexrazoxane-induced cardioprotection.Arch Toxicol2025https://conductscience.org/library/papers/40481868PubMed
38469202Protective effect of coenzyme Q10 against doxorubicin-induced cardiotoxicity: Scoping review article.Saudi Pharm J2024https://conductscience.org/library/papers/38469202PubMed
38175295In vitro evaluation of the reductive carbonyl idarubicin metabolism to evaluate inhibitors of the formation of cardiotoxic idarubicinol via carbonyl and aldo-keto reductases.Arch Toxicol2024https://conductscience.org/library/papers/38175295PubMed
37175180
In Silico and In Vitro Assessment of Carbonyl Reductase 1 Inhibition Using ASP9521-A Potent Aldo-Keto Reductase 1C3 Inhibitor with the Potential to Support Anticancer Therapy Using Anthracycline Antibiotics.
Molecules2023https://conductscience.org/library/papers/37175180PubMed
34926288Intracellular Water Lifetime as a Tumor Biomarker to Monitor Doxorubicin Treatment via FFC-Relaxometry in a Breast Cancer Model.Front Oncol2021https://conductscience.org/library/papers/34926288PubMed
33917090Novel Pyrimidine Derivatives as Potential Anticancer Agents: Synthesis, Biological Evaluation and Molecular Docking Study.Int J Mol Sci2021https://conductscience.org/library/papers/33917090PubMed
33574985Role of Oxidative Stress in the Mechanisms of Anthracycline-Induced Cardiotoxicity: Effects of Preventive Strategies.Oxid Med Cell Longev2021https://conductscience.org/library/papers/33574985PubMed
33526869Label-free spectral imaging to study drug distribution and metabolism in single living cells.Sci Rep2021https://conductscience.org/library/papers/33526869PubMed
33063185Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies.Eur Radiol2021https://conductscience.org/library/papers/33063185PubMed
31955137Carbonyl Reductase 1 Plays a Significant Role in Converting Doxorubicin to Cardiotoxic Doxorubicinol in Mouse Liver, but the Majority of the Doxorubicinol-Forming Activity Remains Unidentified.Drug Metab Dispos2020https://conductscience.org/library/papers/31955137PubMed
30862114The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells.Biomolecules2019https://conductscience.org/library/papers/30862114PubMed
30677473Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.Pharmacol Ther2019https://conductscience.org/library/papers/30677473PubMed
29670334Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas.Drug Des Devel Ther2018https://conductscience.org/library/papers/29670334PubMed
29161764Mechanism of doxorubicin cardiotoxicity evaluated by integrating multiple molecular effects into a biophysical model.Br J Pharmacol2018https://conductscience.org/library/papers/29161764PubMed
28283780Metabolic carbonyl reduction of anthracyclines - role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and chemosensitizing agents.Invest New Drugs2017https://conductscience.org/library/papers/28283780PubMed
27447545Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma.Br J Clin Pharmacol2016https://conductscience.org/library/papers/27447545PubMed
27197003Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.Br J Clin Pharmacol2016https://conductscience.org/library/papers/27197003PubMed
26975227Pharmacogenetics of ABCB5, ABCC5 and RLIP76 and doxorubicin pharmacokinetics in Asian breast cancer patients.Pharmacogenomics J2017https://conductscience.org/library/papers/26975227PubMed
26491536Chemotherapy-Induced Cardiotoxicity: Overview of the Roles of Oxidative Stress.Oxid Med Cell Longev2015https://conductscience.org/library/papers/26491536PubMed

See all 46 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/2890636

GET https://conductscience.org/api/papers/v1/2890636/cited_by?page=2